Trial Profile

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alisertib (Primary)
Indications Malignant-mesothelioma
Focus Therapeutic Use
Sponsors Takeda Oncology

Most Recent Events

03 Feb 2022 Status changed from discontinued to completed.
15 Jun 2021 Planned primary completion date changed from 31 May 2021 to 31 May 2022.
01 Oct 2020 Status changed from active, no longer recruiting to discontinued, as per results published in the Oncologist.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com